Prothena - Stock Price History | PRTA
Historical daily share price chart and data for Prothena since 2023 adjusted for splits. The latest closing stock price for Prothena as of January 27, 2023 is 57.12.
- The all-time high Prothena stock closing price was 78.89 on September 23, 2021.
- The Prothena 52-week high stock price is 66.47, which is 16.4% above the current share price.
- The Prothena 52-week low stock price is 21.06, which is 63.1% below the current share price.
- The average Prothena stock price for the last 52 weeks is 40.05.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Prothena Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
38.8881 |
49.2200 |
65.0000 |
22.7300 |
60.2500 |
21.96% |
| 2021 |
42.2095 |
12.3000 |
78.8900 |
11.0000 |
49.4000 |
311.32% |
| 2020 |
11.7699 |
15.6300 |
15.7700 |
7.5400 |
12.0100 |
-24.13% |
| 2019 |
10.5694 |
10.5000 |
17.0100 |
6.8900 |
15.8300 |
53.69% |
| 2018 |
20.4841 |
37.8000 |
45.0400 |
8.7300 |
10.3000 |
-72.53% |
| 2017 |
54.5062 |
49.7900 |
67.7500 |
35.4400 |
37.4900 |
-23.79% |
| 2016 |
47.9551 |
62.2200 |
67.6400 |
30.1200 |
49.1900 |
-27.78% |
| 2015 |
46.1863 |
20.3500 |
75.3100 |
19.0500 |
68.1100 |
228.08% |
| 2014 |
24.7390 |
28.1000 |
48.3000 |
17.2600 |
20.7600 |
-21.72% |
| 2013 |
14.7389 |
7.0000 |
29.0400 |
5.8400 |
26.5200 |
261.80% |
| 2012 |
6.9833 |
7.2000 |
7.3300 |
6.8000 |
7.3300 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.702B |
$0.201B |
|
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|
